Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: AND014
MIFTS: 41

Androgenic Alopecia

Categories: Skin diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Androgenic Alopecia

About this section

MalaCards integrated aliases for Androgenic Alopecia:

Name: Androgenic Alopecia 12 15
Androgenetic Alopecia 12 73
Alopecia Androgenetica, Male Pattern Baldness 12

Classifications:

MalaCards categories:
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:0050801
ICD10 33 L64
UMLS 73 C0162311
Sources

Summaries for Androgenic Alopecia

About this section
MalaCards based summary : Androgenic Alopecia, also known as androgenetic alopecia, is related to alopecia, androgenetic, 1 and alopecia. An important gene associated with Androgenic Alopecia is SHBG (Sex Hormone Binding Globulin), and among its related pathways/superpathways are Transcription Androgen Receptor nuclear signaling and Coregulation of Androgen receptor activity. The drugs Minoxidil and Finasteride have been mentioned in the context of this disorder. Affiliated tissues include prostate, ovary and skin.

Wikipedia : 76 Pattern hair loss, known as male-pattern hair loss (MPHL) when it affects males and female-pattern hair... more...

Sources

Related Diseases for Androgenic Alopecia

About this section

Diseases related to Androgenic Alopecia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 97)
# Related Disease Score Top Affiliating Genes
1 alopecia, androgenetic, 1 32.3 AR CYP19A1 SHBG
2 alopecia 31.1 AR EDA2R HR SHBG
3 sexual disorder 30.1 KLK3 PRL SHBG
4 prostatic hyperplasia, benign 30.1 AR KLK3 SHBG
5 impotence 30.1 KLK3 PRL SHBG
6 polycystic ovary syndrome 30.0 CYP19A1 PRL SHBG
7 hyperandrogenism 29.8 CYP19A1 PRL SHBG
8 marie unna congenital hypotrichosis 11.4
9 hypotrichosis 1 11.2
10 hypotrichosis simplex 11.2
11 lichen planopilaris 10.3
12 neurofibromatosis, type ii 10.3
13 arteries, anomalies of 10.3
14 coronary artery anomaly 10.3
15 heart disease 10.3
16 frontal fibrosing alopecia 10.3
17 androgen insensitivity syndrome 10.2 AR SHBG
18 47, xxy 10.2 AR SHBG
19 postmenopausal atrophic vaginitis 10.2 AR SHBG
20 sebaceous gland disease 10.2 AR SHBG
21 nodular prostate 10.2 AR KLK3
22 prostate cancer 10.2
23 hypoactive sexual desire disorder 10.2 CYP19A1 SHBG
24 pelvic varices 10.2 PRL SHBG
25 withdrawal disorder 10.2 AR KLK3
26 transsexualism 10.2 AR CYP19A1
27 pityriasis rubra pilaris 10.2
28 coronary heart disease 1 10.2
29 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 10.2
30 dermatitis 10.2
31 psoriasis 10.2
32 gender identity disorder 10.2 AR CYP19A1
33 premenstrual tension 10.2 PRL SHBG
34 cystitis cystica 10.2 AR KLK3
35 male reproductive organ benign neoplasm 10.1 CYP19A1 KLK3
36 oligospermia 10.1 AR PRL
37 alopecia areata 10.1
38 mammographic density 10.1 CYP19A1 PRL
39 stuttering 10.1 CYP19A1 SHBG
40 hypothyroidism, central, and testicular enlargement 10.1 CYP19A1 PRL
41 varicocele 10.1 PRL SHBG
42 male reproductive organ cancer 10.1 AR KLK3 SHBG
43 male reproductive system disease 10.1 AR KLK3 SHBG
44 mccune-albright syndrome 10.1 CYP19A1 PRL
45 androgen insensitivity, partial 10.1 AR CYP19A1 SHBG
46 acanthosis nigricans 10.1 PRL SHBG
47 complete androgen insensitivity syndrome 10.1 AR CYP19A1 SHBG
48 seborrheic dermatitis 10.1 LPP SHBG
49 cryptorchidism, unilateral or bilateral 10.1 AR CYP19A1 SHBG
50 hyperprolactinemia 10.1 PRL SHBG

Graphical network of the top 20 diseases related to Androgenic Alopecia:



Diseases related to Androgenic Alopecia
Sources

Symptoms & Phenotypes for Androgenic Alopecia

About this section
Sources

Drugs & Therapeutics for Androgenic Alopecia

About this section

Drugs for Androgenic Alopecia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 81)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Minoxidil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 38304-91-5 4201
2
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
3 Steroid Synthesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
4 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
5 Hormones Phase 4,Phase 3,Phase 1,Phase 2
6 5-alpha Reductase Inhibitors Phase 4,Phase 3,Phase 1,Phase 2
7 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
8 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
9 Vasodilator Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
10
Dutasteride Approved, Investigational Phase 3,Phase 1 164656-23-9 6918296 152945
11 Pharmaceutical Solutions Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
12
Nitric Oxide Approved Phase 1, Phase 2 10102-43-9 145068
13
Acetylcholine Approved Phase 2 51-84-3 187
14
Bimatoprost Approved, Investigational Phase 2,Phase 1 155206-00-1 5311027
15
Valproic Acid Approved, Investigational Phase 2 99-66-1 3121
16
Vitamin C Approved, Nutraceutical Phase 1, Phase 2,Phase 2 50-81-7 5785 54670067
17
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
18 Proteasome Inhibitors Phase 2
19 HIV Protease Inhibitors Phase 2
20
protease inhibitors Phase 2
21 Adjuvants, Immunologic Phase 2
22 Antiviral Agents Phase 2
23 Ammonium trichloro(dioxoethylene-O,O'-)tellurate Phase 2
24 Protective Agents Phase 2,Phase 1
25 Radiation-Protective Agents Phase 2
26 Anti-Infective Agents Phase 2,Not Applicable
27 Immunologic Factors Phase 2
28 Endothelium-Dependent Relaxing Factors Phase 1, Phase 2
29 Anti-Asthmatic Agents Phase 1, Phase 2
30 Neurotransmitter Agents Phase 1, Phase 2,Phase 2
31 Antioxidants Phase 1, Phase 2
32 Autonomic Agents Phase 1, Phase 2
33 Respiratory System Agents Phase 1, Phase 2
34 Free Radical Scavengers Phase 1, Phase 2
35 Bronchodilator Agents Phase 1, Phase 2
36 Peripheral Nervous System Agents Phase 1, Phase 2
37 Mitogens Phase 1, Phase 2,Not Applicable
38 Androgens Phase 2,Phase 1
39 Acetylcholine Release Inhibitors Phase 2
40 Botulinum Toxins, Type A Phase 2
41 Cholinergic Agents Phase 2
42 Botulinum Toxins Phase 2
43 onabotulinumtoxinA Phase 2
44 abobotulinumtoxinA Phase 2
45 Ophthalmic Solutions Phase 2
46 Psychotropic Drugs Phase 2
47 Central Nervous System Depressants Phase 2
48 Tranquilizing Agents Phase 2
49 Anticonvulsants Phase 2
50 GABA Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 115)
# Name Status NCT ID Phase Drugs
1 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Unknown status NCT02999737 Phase 4
2 Adipose Derived Stem Cells Versus Platelet Rich Plasma on Follicular Unit Extraction Recruiting NCT03388840 Phase 4
3 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
4 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
5 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
6 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
7 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
8 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
9 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
10 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
11 Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia Completed NCT03004469 Phase 3 P-3074;Finasteride;Vehicle
12 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
13 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
14 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
15 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
16 A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia Recruiting NCT03742518 Phase 2, Phase 3 Topical SM04554 solution;Topical SM04554 solution;Topical vehicle solution
17 Efficacy and Safety Study to Compare Topical Herbal Solution and Minoxidil 5% in Male Pattern Hair Loss Recruiting NCT03753113 Phase 3 Topical Minoxidil 5%
18 Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia Unknown status NCT01501617 Phase 1, Phase 2
19 Treatment of Androgenetic Alopecia in Males With Theradomeâ„¢ LH80 PRO Unknown status NCT02528552 Phase 2
20 A Study to Determine the Safety and Efficacy of Autologous Human Platelet Lysate for Treatment of Androgenetic Alopecia Unknown status NCT01643629 Phase 1, Phase 2
21 Study To Determine Safety & Efficacy Of Autologous Human Platelet Lysate in Androgenetic Alopecia After Hair Transplant Unknown status NCT01644422 Phase 1, Phase 2
22 Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Unknown status NCT00471510 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
23 Topical AS101 for Treatment of FAGA (Female Androgenetic Alopecia) in Menopause Women Unknown status NCT00418249 Phase 2 AS101
24 Efficacy and Safety Comparing 5% Monoxidil Milky Lotion Versus 5% Minoxidil Solution in Androgenetic Alopecia Unknown status NCT01650272 Phase 1, Phase 2 5% MInoxidil milky lotion;5% Minoxidil solution
25 Safety and Efficacy of Nitric Oxide Gel in Promoting Hair Growth in Male Human Subjects With Androgenetic Alopecia Unknown status NCT01347957 Phase 1, Phase 2
26 A Study of SM04554 Applied Topically to the Scalp of Male Subjects With Androgenetic Alopecia Analyzed by Biopsy of the Scalp Prior To and Post Dosing Completed NCT02503137 Phase 2 Topical SM04554 solution;Topical Vehicle solution
27 Safety and Efficacy Study of Human Autologous Hair Follicle Cells to Treat Androgenetic Alopecia Completed NCT01286649 Phase 1, Phase 2
28 A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA) Completed NCT02275351 Phase 2 SM04554;Vehicle
29 A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia Completed NCT02279823 Phase 2 CB-03-01 solution;Minoxidil Solution 5%;Placebo solution
30 Adipose Tissue Derived Stem Cell Based Hair Restoration Therapy for Androgenetic Alopecia Completed NCT02865421 Phase 2 stem cells;platelet rich plasma
31 Treatment of Male Pattern Baldness With Botulinum Toxin Completed NCT00965640 Phase 2 Botulinum Toxin - A injections
32 Effectiveness and Safety of Minoxidil Foam Versus Placebo Foam for Androgenetic Alopecia Completed NCT01319370 Phase 2 Minoxidil;vehicle of 5% Minoxidil topical foam
33 Efficacy of Nutrition Supplement for Treatment of Men With Hair Loss Completed NCT02150187 Phase 2
34 Phase 2A Study of Setipiprant Tablets in Androgenetic Alopecia in Males Completed NCT02781311 Phase 2 setipiprant;placebo
35 Clinical Trial to Explore the Efficacy and Safety of DA-4001 After Topical Application Completed NCT02280603 Phase 1, Phase 2 DA-4001C;5% minoxidil
36 Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss Completed NCT00418730 Phase 2 tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
37 A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA) Completed NCT01904721 Phase 2 Bimatoprost Solution 1;Bimatoprost Solution 2;Bimatoprost Vehicle
38 Safety and Efficacy Study of Bimatoprost in the Treatment of Men With Androgenic Alopecia Completed NCT01325337 Phase 2 bimatoprost Formulation A;bimatoprost Formulation B;bimatoprost Formulation C;bimatoprost vehicle solution;minoxidil 5% solution
39 Topical Bimatoprost Effect on Androgen Dependent Hair Follicles Completed NCT02170662 Phase 2 Bimatoprost;Placebo
40 STYLE -- A Trial of Cell Enriched Adipose For Androgenetic Alopecia Completed NCT02503852 Phase 2
41 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004512) Completed NCT01451125 Phase 2
42 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931) Completed NCT01669746 Phase 2
43 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0005995) Completed NCT01451190 Phase 2
44 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669) Completed NCT01451177 Phase 2
45 A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004542) Completed NCT01451151 Phase 2
46 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541) Completed NCT01451138 Phase 2
47 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002899) Completed NCT01451112 Phase 2
48 A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss Completed NCT01451099 Phase 2
49 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002013) Completed NCT01451073 Phase 2
50 A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012) Completed NCT01451047 Phase 2

Search NIH Clinical Center for Androgenic Alopecia

Sources

Genetic Tests for Androgenic Alopecia

About this section
Sources

Anatomical Context for Androgenic Alopecia

About this section

MalaCards organs/tissues related to Androgenic Alopecia:

41
Prostate, Ovary, Skin, Testes, Bone, Heart, Breast
Sources

Publications for Androgenic Alopecia

About this section

Articles related to Androgenic Alopecia:

(show top 50) (show all 730)
# Title Authors Year
1
Possible association between androgenic alopecia and risk of prostate cancer and testicular germ cell tumor: a systematic review and meta-analysis. ( 29529997 )
2018
2
Prescribing Habits for Androgenic Alopecia Among Dermatologists in Spain in 2017: A Cross-Sectional Study. ( 29656764 )
2018
3
Platelet-Rich Plasma for the Treatment of Androgenic Alopecia: A Systematic Review. ( 29954021 )
2018
4
Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. ( 29981403 )
2018
5
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia. ( 29443105 )
2018
6
Comparison of the Efficacy of Homologous and Autologous Platelet-Rich Plasma (PRP) for Treating Androgenic Alopecia. ( 29101437 )
2018
7
A hypothetical pathogenesis model for androgenic alopecia: clarifying the dihydrotestosterone paradox and rate-limiting recovery factors. ( 29407002 )
2018
8
A proprietary herbal extract against hair loss in androgenetic alopecia and telogen effluvium: a placebo-controlled, single-blind, clinical-instrumental study. ( 29945259 )
2018
9
Quality of Life with Alopecia Areata versus Androgenetic Alopecia Assessed Using Hair Specific Skindex-29. ( 29853767 )
2018
10
Androgenic alopecia in a postmenopausal Sicilian baroness. ( 29103134 )
2018
11
A Meta-analysis On Evidence Of Platelet-rich Plasma for Androgenetic Alopecia. ( 29440850 )
2018
12
A randomized, double-blind controlled study of the efficacy and safety of topical solution of 0.25% finasteride admixed with 3% minoxidil versus 3% minoxidil solution in the treatment of male androgenetic alopecia. ( 29972712 )
2018
13
Efficacy and Safety of a Low-Level Light Therapy for Androgenetic Alopecia: A 24-Week, Randomized, Double-Blind, Self-Comparison, Sham Device-Controlled Trial. ( 29957664 )
2018
14
Low-level laser therapy for the treatment of androgenic alopecia: a review. ( 29270707 )
2018
15
Distinguishing immunohistochemical features of alopecia areata from androgenic alopecia. ( 29790258 )
2018
16
Use of Minoxidil Sulfate versus Minoxidil Base in Androgenetic Alopecia Treatment: Friend or Foe? ( 30410915 )
2018
17
Acne development in male androgenetic alopecia. ( 30499125 )
2018
18
Evaluation of long-term efficacy of finasteride in Korean men with androgenetic alopecia using the basic and specific classification system. ( 30536893 )
2018
19
Dermoscopic pre- and posttreatment evaluation in patients with androgenetic alopecia on platelet-rich plasma-A prospective study. ( 30556270 )
2018
20
Minoxidil in the treatment of androgenetic alopecia. ( 30155952 )
2018
21
Comparison of quality of life in patients with androgenetic alopecia and alopecia areata. ( 30156613 )
2018
22
Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils. ( 30169980 )
2018
23
The new paradigm for androgenetic alopecia and plant-based folk remedies: 5α-reductase inhibition, reversal of secondary microinflammation and improving insulin resistance. ( 30195058 )
2018
24
Efficacy and Safety of a Topical Botanical in Female Androgenetic Alopecia: A Randomized, Single-Blinded, Vehicle-Controlled Study. ( 30197894 )
2018
25
Adverse Sexual Effects of Treatment with Finasteride or Dutasteride for Male Androgenetic Alopecia: A Systematic Review and Meta-analysis. ( 30206635 )
2018
26
Finasteride and Erectile Dysfunction in Patients with Benign Prostatic Hyperplasia or Male Androgenetic Alopecia. ( 30209896 )
2018
27
Estimation of Zinc and Iron Levels in the Serum and Hair of Women with Androgenetic Alopecia: Case-control Study. ( 30210156 )
2018
28
Synergistic effect of platelet-rich plasma injections and scalp lifting in androgenetic alopecia. ( 30217282 )
2018
29
Low-dose daily aspirin reduces topical minoxidil efficacy in androgenetic alopecia patients. ( 30226287 )
2018
30
Shedding light on the FDA's 510(k) approvals process: low-level laser therapy devices used in the treatment of androgenetic alopecia. ( 30252550 )
2018
31
Controversies in the treatment of androgenetic alopecia: The history of finasteride. ( 30253001 )
2018
32
Platelet-rich plasma for androgenic alopecia treatment: A comprehensive review. ( 30261560 )
2018
33
Sexual Problems of Men With Androgenic Alopecia Treated With 5-Alpha Reductase Inhibitors. ( 30301703 )
2018
34
Serum Levels of Androgen-Associated Hormones Are Correlated with Curative Effect in Androgenic Alopecia in Young Men. ( 30376555 )
2018
35
Impact on Quality of Life in Patients who came with Androgenetic Alopecia for Hair Transplantion Surgery in a Clinic. ( 30387465 )
2018
36
Efficacy of platelet-rich plasma in androgenetic alopecia patients. ( 30393988 )
2018
37
HrQoL in hair loss-affected patients with alopecia areata, androgenetic alopecia and telogen effluvium: the role of personality traits and psychosocial anxiety. ( 30394586 )
2018
38
Evaluation of the Expression of Genes Associated with Inflammation and Apoptosis in Androgenetic Alopecia by Targeted RNA-Seq. ( 30410894 )
2018
39
Platelet-rich plasma on female androgenetic alopecia: Tested on 10 patients. ( 29707872 )
2018
40
Letter to the Editor: androgenetic alopecia; drug safety and therapeutic strategies. ( 29707969 )
2018
41
Response to the letter to the editor; Androgenetic alopecia; drug safety and therapeutic strategies. ( 29707983 )
2018
42
The tendency towards the development of psychosexual disorders in androgenetic alopecia according to the different stages of hair loss: a cross-sectional study. ( 29723381 )
2018
43
Bayesian measurement-error-driven hidden Markov regression model for calibrating the effect of covariates on multistate outcomes: Application to androgenetic alopecia. ( 29785802 )
2018
44
Systematic review of platelet-rich plasma (PRP) preparation and composition for the treatment of androgenetic alopecia. ( 29790267 )
2018
45
Efficacy of non-surgical treatments for androgenetic alopecia: a systematic review and network meta-analysis. ( 29797431 )
2018
46
New Perspectives on the Treatment of Androgenetic Alopecia. ( 29801692 )
2018
47
Association of Androgenetic Alopecia with Metabolic Syndrome: A Case-control Study on 100 Patients in a Tertiary Care Hospital in South India. ( 29911030 )
2018
48
Insights into Male Androgenetic Alopecia: Differential Gene Expression Profiling of Plucked Hair Follicles and Integration with Genetic Data. ( 30009830 )
2018
49
The effectiveness of adding low-level light therapy to minoxidil 5% solution in the treatment of patients with androgenetic alopecia. ( 30027912 )
2018
50
White and yellow dots as new trichoscopic signs of severe female androgenetic alopecia in dark skin phototypes. ( 30043983 )
2018
Sources

Variations for Androgenic Alopecia

About this section
Sources

Expression for Androgenic Alopecia

About this section
Search GEO for disease gene expression data for Androgenic Alopecia.
Sources

Pathways for Androgenic Alopecia

About this section

Pathways related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Transcription Androgen Receptor nuclear signaling 22
Show member pathways
 11.3 AR KLK3 WNT10A
2
Coregulation of Androgen receptor activity 1
11.12 AR KLK3
3
Regulation of Androgen receptor activity 1
11.02 AR KLK3
4
FOXA1 transcription factor network 1
Show member pathways
 10.92 AR KLK3
5
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.81 AR CYP19A1
6
Nongenotropic Androgen signaling 1
9.88 AR SHBG
Sources

GO Terms for Androgenic Alopecia

About this section

Biological processes related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mammary gland development GO:0030879 9.26 CYP19A1 PRL
2 regulation of systemic arterial blood pressure GO:0003073 9.16 AR KLK3
3 negative regulation of angiogenesis GO:0016525 9.13 EFNA3 KLK3 PRL
4 prostate gland growth GO:0060736 8.62 AR CYP19A1

Molecular functions related to Androgenic Alopecia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.96 AR SHBG
2 androgen binding GO:0005497 8.62 AR SHBG
Sources

Sources for Androgenic Alopecia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....